This launch represents an important step in Roche’s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine. Each year 300,000 patients around the world are diagnosed with triple-negative breast cancer, an aggressive disease with limited treatment options1,2 VENTANA PD-L1 (SP142) Assay helps identify triple-negative breast cancer patients most … Continue reading Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq